LB0010 INHIBITION OF STRUCTURAL DAMAGE PROGRESSION WITH GUSELKUMAB, A SELECTIVE IL-23i, IN PARTICIPANTS WITH ACTIVE PsA: RESULTS THROUGH WEEK 24 OF THE PHASE 3b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED APEX STUDY

Authors
Category Primary study
ConferenceAnnals of the Rheumatic Diseases
Year 2025
This article has no abstract
Epistemonikos ID: 1d17ef8c524d21b20d9f814dbb1252ffe511e83b
First added on: Apr 29, 2026